Abstract:

Hyperlipidemia in animals refers to the disorder of plasma lipid metabolism in the body, mainly including the increase of plasma total cholesterol, triglyceride and low-density lipoprotein cholesterol, as well as the decrease of high-density lipoprotein cholesterol. The hyperlipidemia in animals can lead to the disorders of lipid metabolism, which in turn leads to the occurrence and development of metabolic diseases such as Type 2 diabetes and insulin resistance. LKB1-AMPKα signaling pathway plays an important role in the regulation of hyperlipidemia in animals. AMPK is a serine/threonine kinase, which is called “cell energy monitor”, LKB1 is the upstream kinase of AMPK, LKB1 and AMPKα interact and co-regulate the hyperlipidemia. Therefore, clarifying the upstream and downstream signaling pathways of LKB1 and AMPK interactions may become a new target for treatment of metabolic diseases such as hyperlipidemia. This article reviews the role of LKB1-AMPKα signaling pathways in the development and progression of hyperlipidemia, and the aims are to provide theoretical support for further research on the regulation mechanism of signaling transduction pathways associated with hyperlipidemia in animals.

Key words: LKB1, AMPKα, animals, hyperlipidemia, regulation